<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Residual kidney function in kidney failure</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Residual kidney function in kidney failure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Residual kidney function in kidney failure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony Bleyer, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Connie Rhee, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Many patients starting dialysis have significant residual kidney function. According to the United States Renal Data System, only 15 percent of individuals starting dialysis in 2020 had an estimated glomerular filtration rate (eGFR) &lt;5 mL/min/1.73 m<sup>2</sup> [<a href="#rid1">1</a>].</p><p>Preservation of this residual kidney function has been associated with improved outcomes, and nephrologists should try to preserve this residual kidney function as long as possible. However, while residual kidney function is beneficial to patients on dialysis, patients should <strong>not</strong> be initiated on dialysis earlier to take advantage of more abundant residual kidney function as this has not been associated with improved outcomes.</p><p>Even when the eGFR is very low, the urine output is variable, ranging from oliguria to normal levels. Volume expansion (due to sodium retention) and a urea osmotic diuresis (as the daily urea load is excreted by fewer functioning nephrons) play an important role in preserving urine output in the setting of advanced chronic kidney disease (CKD) [<a href="#rid2">2-4</a>].</p><p>This topic will review the clinical importance of residual kidney function in patients with kidney failure and factors that may affect residual kidney function in this patient population.</p><p class="headingAnchor" id="H1824086739"><span class="h1">CLINICAL IMPORTANCE OF RESIDUAL KIDNEY FUNCTION</span><span class="headingEndMark"> — </span>There are two essential components to residual kidney function: clearance of uremic toxins and urinary volume. The loss of residual kidney function in patients with end-stage kidney disease (ESKD) has important clinical manifestations, including adverse effects upon volume control, patient survival, health-related quality of life, and other clinical parameters [<a href="#rid5">5-12</a>].</p><p class="headingAnchor" id="H1122805873"><span class="h2">Clearance of uremic toxins</span><span class="headingEndMark"> — </span>Although the remaining glomerular filtration rate (GFR) may only be 4 to 5 mL/min in patients initiated on maintenance dialysis, this is sufficient to make a significant contribution to the removal of potential uremic toxins since filtration is continuous, as opposed to the 12 hours per week that the patient is undergoing hemodialysis [<a href="#rid13">13</a>]. In addition, residual kidney function allows for the clearance of larger molecules, such as beta-2 microglobulin, which dialysis filters cannot remove. Thus, this residual function encompasses more than the urea clearance that can be calculated as a contribution to dialysis dose. Even in patients with residual kidney volume less than 1.5 mL/min, patients who were not anuric had significantly lower levels of nonurea solutes such as indoxyl sulfate and asymmetric dimethylarginine than patients on dialysis [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H3113848915"><span class="h2">Volume control</span><span class="headingEndMark"> — </span>Urine output is an essential function of the kidney and has a significant effect on the quality of life of patients on hemodialysis. As an example, a residual urinary output of just 1 liter/day will equate to 3 liters over the weekend interval, which is beneficial to the patient. The increased urine output may allow for increased fluid intake by that patient and also necessitate less fluid removal with dialysis. This decreases cramping and the possibility of intradialytic hypotension, which can lead to myocardial stunning, ischemia, and increased mortality [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/1945.html" rel="external">"Intradialytic hypotension in an otherwise stable patient", section on 'Outcomes'</a>.)</p><p>In peritoneal dialysis, the need to remove less fluid allows for the use of dialysate with a lower glucose concentration, decreasing the caloric intake from peritoneal dialysis and the toxicity of glucose and glucose intermediates to the peritoneal membrane [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/1905.html" rel="external">"Peritoneal dialysis solutions", section on 'Low-molecular-weight agents'</a>.)</p><p class="headingAnchor" id="H405499271"><span class="h2">Survival</span><span class="headingEndMark"> — </span>Among patients on peritoneal dialysis or hemodialysis, the beneficial effect of continued residual kidney function on survival is clear, as shown in the CANUSA study, a large study of Canadian and United States patients on peritoneal dialysis [<a href="#rid17">17</a>]; the Netherlands Cooperative Study of the Adequacy of Dialysis (NECOSAD), a study of 1800 patients on hemodialysis and peritoneal dialysis; and others [<a href="#rid8">8-11,18,19</a>]. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">"Prescribing peritoneal dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a>.)</p><p>In patients on dialysis, the magnitude of the association between residual kidney function and improved survival is illustrated by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of over 600 incident patients on peritoneal dialysis, there was a 36 percent reduction in relative risk of death with increased urine volume; residual GFR was not associated with improved mortality [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study including over 700 incident patients on hemodialysis, preservation of urine output of greater than 250 mL/day was associated with a 30 percent reduction in all-cause mortality [<a href="#rid8">8</a>]. </p><p></p><p>Thus, one should adopt measures aimed at preserving residual kidney function among patients on peritoneal dialysis and hemodialysis and improving endogenous fluid removal through increased urine volume. Even if urea clearance is small, the urinary volume is beneficial. (See <a class="local">'Factors that may affect residual kidney function'</a> below.)</p><p class="headingAnchor" id="H1998606436"><span class="h2">Health-related quality of life and other clinical parameters</span><span class="headingEndMark"> — </span>Among patients on dialysis, residual kidney function is associated with better quality of life [<a href="#rid8">8,12</a>]. In addition, observational data suggest that residual kidney function may confer the following benefits:</p><p class="bulletIndent1"><span class="glyph">●</span>Less inflammation, as defined by C-reactive protein and interleukin 6 levels [<a href="#rid8">8</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased responsiveness to erythropoietin stimulating agents [<a href="#rid8">8,20</a>] </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improved nutritional status [<a href="#rid21">21</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fewer dietary restrictions [<a href="#rid22">22</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased chronic kidney disease–associated pruritus [<a href="#rid23">23</a>]</p><p></p><p class="headingAnchor" id="H2341728799"><span class="h1">EFFECTS OF DIALYSIS ON RESIDUAL KIDNEY FUNCTION</span><span class="headingEndMark"> — </span>Both volume expansion and the high urea load per nephron are rapidly reversed by dialysis (of any form), which removes sodium, water, and urea. Thus, it is not surprising that many patients have a marked reduction in, or even cessation of, urine output when dialysis is instituted [<a href="#rid2">2</a>]. This observation has raised the question of whether dialysis itself worsens residual kidney function. This issue is unresolved in acute kidney failure. (See  <a class="medical medical_review" href="/z/d/html/1938.html" rel="external">"Dialysis-related factors that may influence recovery of kidney function in acute kidney injury (acute renal failure)"</a>.)</p><p>Peritoneal and hemodialysis may have different effects on residual kidney function, as discussed in the following sections.</p><p class="headingAnchor" id="H1147023157"><span class="h2">Hemodialysis</span><span class="headingEndMark"> — </span>Evidence suggests that the institution of maintenance hemodialysis alone may accelerate injury to the few nephrons that are still functioning at the onset of dialysis [<a href="#rid24">24</a>], presumably due to ischemic insults (from intradialytic hypotension and/or postdialysis hypovolemia), exposure to nephrotoxic mediators (from dialysis tubing and impurities), and deactivation of remaining nephrons [<a href="#rid25">25,26</a>]. This injury results in a progressive fall in the residual glomerular filtration rate (GFR) [<a href="#rid13">13,27-30</a>].</p><p>The characteristics of the hemodialysis procedure may affect the rate of loss of function:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biocompatible membranes</strong> – Hemodialysis with biocompatible membranes may better preserve residual kidney function compared with bioincompatible membranes [<a href="#rid31">31-33</a>]. (See  <a class="medical medical_review" href="/z/d/html/1873.html" rel="external">"Clinical consequences of hemodialysis membrane biocompatibility"</a>.)</p><p></p><p class="bulletIndent1">Most of the studies in this area have suffered from methodologic flaws or small sample sizes. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a multicenter trial that randomly assigned 159 incident patients on hemodialysis to dialysis with high-flux membranes or low-flux bioincompatible membranes, there was no significant difference in the rate of change of kidney function, although the residual kidney function at the start of the study was quite low (approximately 1 mL/min in the bioincompatible membrane group and 0.7 mL/min in the control group) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial that randomly assigned 20 patients on dialysis to dialysis with either cellulose or polysulfone membranes, there was better preservation of residual kidney function in the polysulfone group at one year [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysate </strong>– The possible role of the hemodialysis dialysate was addressed in a trial in which 30 patients initiating hemodialysis were randomly assigned to dialysis using either conventional or ultrapure dialysate [<a href="#rid36">36</a>]. Residual kidney function in the ultrapure group was significantly higher at 24 months (4.3 versus 2.5 mL/min). Markers of inflammation, such as C-reactive protein, were also significantly lower among these patients. (See  <a class="medical medical_review" href="/z/d/html/1948.html" rel="external">"Ultrapure dialysis fluid"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency of dialysis </strong>– More frequent hemodialysis may accelerate the loss of residual kidney function:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One study evaluated residual kidney function in participants of the Frequent Hemodialysis Network (FHN) Daily and Nocturnal trials [<a href="#rid37">37</a>]. Patients assigned to frequent nocturnal dialysis (six times per week) had significantly lower urine volume and urea clearance at 4 and 12 months compared with conventional nocturnal dialysis (three times per week). There was no significant difference in loss of urine volume or residual kidney function in patients who did frequent versus conventional daily dialysis, although there was likely not enough statistical power to identify a difference.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective review of patients who initiated dialysis in a large dialysis organization in the US, among 351 individuals who started hemodialysis with fewer than three treatments per week, both kidney urea clearance and urine volume declined more slowly over time compared with a matched cohort of 8065 patients who dialyzed three times weekly [<a href="#rid38">38</a>]. The median kidney urea clearance and urine volume were 4.8 mL/min/1.73 m<sup>2</sup> and 1150 mL in the less frequent dialysis group versus 3.04 mL/min/1.73 m<sup>2</sup> and 800 mL in the conventional dialysis group. There was no difference in survival between the two groups. However, in a subgroup analysis of patients who had a baseline kidney urea clearance &lt;3 mL/min/1.73 m<sup>2</sup>, those who started twice-weekly hemodialysis experienced higher mortality compared with those in the conventional hemodialysis group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incremental dialysis </strong>– Incremental hemodialysis is a method of dosing hemodialysis by which residual kidney function is incorporated into the calculation of hemodialysis dose. Including residual kidney function can lead to the need for less than three hemodialysis treatments per week, shorter treatments, or less intense treatments. (See  <a class="medical medical_review" href="/z/d/html/97967.html" rel="external">"Incorporating residual kidney function into the dosing of intermittent hemodialysis"</a>.)</p><p></p><p class="bulletIndent1">Whether incremental dialysis helps to preserve residual kidney function is unclear. In a multicenter feasibility trial that randomly assigned 55 incident patients on hemodialysis with a urea clearance of ≥3 mL/min/1.73 m<sup>2</sup> to conventional hemodialysis (three times weekly for 3.5 to 4 hours) or incremental hemodialysis (twice weekly, upwardly adjusting hemodialysis dose as residual kidney function was lost) for 12 months, there was no change in the urea clearance slope between the two treatment arms [<a href="#rid39">39</a>]. Larger studies and multisite clinical trials are in progress that will address this question [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultrafiltration rate </strong>– Higher ultrafiltration rates during hemodialysis are associated with faster declines in residual kidney function. In a study of over 7700 incident patients on conventional, thrice weekly hemodialysis, higher ultrafiltration rates were associated with a greater decline in urine output after one year [<a href="#rid41">41</a>]. Similarly, in another study of over 1500 incident patients on an incremental hemodialysis regimen, higher ultrafiltration rates were associated with faster loss of residual kidney function [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H445359293"><span class="h2">Peritoneal dialysis</span><span class="headingEndMark"> — </span>Certain features of peritoneal dialysis may affect residual kidney function:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modality </strong>– Although some studies suggest that automated forms of peritoneal dialysis (APD) might be associated with a more rapid decline in residual kidney function [<a href="#rid43">43-45</a>], other studies have found minimal effect of peritoneal dialysis modality on the loss of residual kidney function [<a href="#rid46">46-48</a>]. The effect of peritoneal dialysis modality on the patient's quality of life should be more important in determining modality than possible effects on residual kidney function decline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="113932" href="/z/d/drug information/113932.html" rel="external">Peritoneal dialysis solutions</a><strong> </strong>– Some [<a href="#rid49">49,50</a>], but not all [<a href="#rid51">51-54</a>], studies have suggested that more biocompatible peritoneal dialysis solutions, specifically those with low glucose degradation products and a neutral pH, preserve residual kidney function. In a 2015 meta-analysis of six trials, patients who underwent peritoneal dialysis with these biocompatible solutions had a slower rate of decline of residual kidney function, a higher achieved Kt/V, and a higher urine volume compared with patients who were treated with conventional peritoneal dialysis solutions [<a href="#rid55">55</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8769" href="/z/d/drug information/8769.html" rel="external">Icodextrin</a> solution has also been compared with biocompatible <a class="drug drug_general" data-topicid="113932" href="/z/d/drug information/113932.html" rel="external">peritoneal dialysis solutions</a>. In one trial, there was no difference in residual kidney function between groups at one year [<a href="#rid56">56</a>]. However, patients using icodextrin had a slower decline in urine volume compared with patients using biocompatible solutions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight gain </strong>– Preventing weight gain may preserve residual kidney function. One study analyzed the effect of weight gain on residual kidney function among 148 patients on peritoneal dialysis [<a href="#rid57">57</a>]. In a multivariate model, patients with a weight increase greater than 2.3 kg had a fourfold increased risk of loss of residual kidney function. Other variables in the model that predicted faster loss of kidney function included diabetes mellitus, proteinuria, elevated C-reactive protein, and elevated systolic blood pressure. Additional studies are needed to confirm these findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other factors </strong>– In another study of patients on peritoneal dialysis (the balANZ trial), better preservation of residual kidney function was associated with male sex, higher baseline residual kidney function, higher systolic blood pressure, biocompatible fluids, lower peritoneal ultrafiltration, and lower dialysate glucose exposure [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">Other risk factors for developing anuria among patients on peritoneal dialysis include serum bicarbonate &lt;24 mEq/L [<a href="#rid59">59</a>] and development of peritonitis [<a href="#rid60">60</a>]. </p><p></p><p class="headingAnchor" id="H2822217422"><span class="h2">Hemodialysis versus peritoneal dialysis</span><span class="headingEndMark"> — </span>For reasons that are incompletely understood, the loss of residual kidney function appears to occur more rapidly with hemodialysis than with peritoneal dialysis [<a href="#rid13">13,27-30</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 279 patients on hemodialysis and 243 patients on peritoneal dialysis, loss of residual kidney function was greater in patients on hemodialysis than in those on peritoneal dialysis, with patients on peritoneal dialysis on average having a 30 percent higher residual GFR than those on hemodialysis [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 811 patients on hemodialysis and 1032 patients on peritoneal dialysis, patients on peritoneal dialysis had a 65 percent lower risk of oliguria (self-reported urine volume &lt;200 mL/day) at one year of follow-up compared with those on hemodialysis [<a href="#rid28">28</a>].</p><p></p><p>However, it is important to note that many of the studies addressing this issue are older, and, at the time, modern hemodialytic techniques such as volumetric control, ultrapure water, and biocompatible membranes were not in use. Residual kidney function has also been studied extensively in the peritoneal dialysis population, but there have been few studies in the hemodialysis population. It is reasonable to mention to patients who are preparing for dialysis that residual kidney function is likely better preserved using peritoneal dialysis rather than hemodialysis. However, survival with either modality appears to be equivalent, and lifestyle preferences should remain the predominant factor when choosing dialysis modality. (See  <a class="medical medical_review" href="/z/d/html/1844.html" rel="external">"Dialysis modality and patient outcome"</a>.)</p><p>Potential reasons for differences in loss of residual kidney function with hemodialysis include more frequent exposure to ischemic injury from intermittent hypotension and activation of nephrotoxic inflammatory mediators during treatments [<a href="#rid30">30,61,62</a>]. In one study of 522 patients initiating either peritoneal dialysis or hemodialysis, predictors of the rate of decline in residual kidney function at baseline included a higher diastolic blood pressure and increased proteinuria [<a href="#rid30">30</a>]. Over time, decreases in residual kidney function were associated with hypotension with hemodialysis and dehydration episodes with peritoneal dialysis. Relatively higher kidney function was consistently observed with peritoneal dialysis, which increased over time. (See  <a class="medical medical_review" href="/z/d/html/1945.html" rel="external">"Intradialytic hypotension in an otherwise stable patient"</a>.)</p><p>Another possible explanation for the different effect upon residual kidney function is that volume expansion with continuous peritoneal dialysis may help to preserve kidney function [<a href="#rid30">30,61,63</a>]. In one study that examined volume control versus the use of antihypertensive agents for control of hypertension in patients on hemodialysis with a baseline urine production of approximately 1600 mL/day, urine output dropped by only 12 percent during treatment with antihypertensive medications, but, with the use of volume removal, urine output decreased to &lt;200 mL/day in all patients [<a href="#rid63">63</a>]. Blood pressure control improved, and left ventricular mass decreased significantly with volume removal.</p><p>As mentioned above, newer hemodialytic techniques may result in a slower rate of decline of residual kidney function. In one study, the loss of residual kidney function was similar in a comparison of 175 patients receiving continuous ambulatory peritoneal dialysis (CAPD) versus 300 patients dialyzed with ultrapure water, bicarbonate buffer, and high-flux polysulphone membranes [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H2085334358"><span class="h1">FACTORS THAT MAY AFFECT RESIDUAL KIDNEY FUNCTION</span></p><p class="headingAnchor" id="H1552115563"><span class="h2">Intradialytic hypotension</span><span class="headingEndMark"> — </span>It is important to avoid hypotension with or after dialysis. Hypotension during dialysis not only causes myocardial, cerebrovascular, and mesenteric ischemia but can also lead to decreased kidney perfusion and loss of kidney function. (See  <a class="medical medical_review" href="/z/d/html/1945.html" rel="external">"Intradialytic hypotension in an otherwise stable patient"</a>.)</p><p>Hypotension may result from attempts to challenge the target weight (ie, reduce the target weight) in an effort to achieve euvolemia in patients who are just starting dialysis. Among patients who start dialysis with reasonable residual kidney function, attempts to aggressively remove fluid may result in low blood pressures that can cause progressive loss of kidney function, even in the absence of symptoms such as cramping or presyncope [<a href="#rid64">64</a>].</p><p>When a patient is new to dialysis, if blood pressure is well controlled and there is no edema or heart failure present, aggressive fluid removal should be avoided, and the patient should be "run even" without fluid removal. The physician should be alerted if hypotension develops. However, when a patient is new to dialysis and has persistent hypertension, edema, or heart failure, volume removal should be considered, with an effort to avoid hypotension.</p><p class="headingAnchor" id="H1727174834"><span class="h2">Diuretics</span><span class="headingEndMark"> — </span>Unless urine output is negligible, diuretics should be continued in patients who initiate dialysis. Loop diuretics increase urine and sodium excretion (though they do not affect residual kidney function) [<a href="#rid65">65</a>] and decrease the need for volume removal with dialysis [<a href="#rid7">7</a>]. In a trial of 61 patients on peritoneal dialysis randomly assigned to either <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> (250 mg/day) or no furosemide, urine volume at 6 and 12 months was significantly higher in the group receiving the diuretic, although clearance of creatinine and urea had declined at a similar rate in both groups [<a href="#rid65">65</a>].</p><p>There are no evidence-based guidelines or safety data for chronic dosing of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> in patients on hemodialysis or peritoneal dialysis. In one study, chronic daily administration of 250 to 2000 mg of furosemide resulted in sun-induced bullous dermatosis in 3 of 10 patients without evidence of ototoxicity [<a href="#rid66">66</a>]. While furosemide has been associated with deafness, there are no reported cases of deafness from furosemide in patients with end-stage kidney disease (ESKD) receiving furosemide. In the author's experience, doses of furosemide up to 120 mg orally each day with 5 mg <a class="drug drug_general" data-topicid="9644" href="/z/d/drug information/9644.html" rel="external">metolazone</a> are in general well tolerated. While these agents confer significant benefit in terms of increased urinary volume, the lack of clinical safety data, benefits, risks, and alternatives should be discussed with the patient. It is important that these agents be stopped when urine output becomes negligible and patients be monitored for hearing loss and skin changes.</p><p class="headingAnchor" id="H4043995799"><span class="h2">Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers</span><span class="headingEndMark"> — </span>The preservation of residual kidney function among those undergoing peritoneal dialysis may be enhanced by the administration of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB). In a 2014 Cochrane review of six nonblinded trials and 257 patients, the decline in eGFR was modestly smaller at 12 months among patients who were treated with an ACE inhibitor or an ARB [<a href="#rid67">67</a>]. Among patients on hemodialysis, results from small trials of ACE inhibitors or ARBs compared with placebo for preservation of residual kidney function are conflicting [<a href="#rid68">68,69</a>].</p><p>Based on these findings, the use of ACE inhibitors or ARBs is recommended to help preserve residual kidney function in those who require antihypertensive medications [<a href="#rid70">70,71</a>]. </p><p class="headingAnchor" id="H2394223625"><span class="h2">Nephrotoxic agents</span></p><p class="headingAnchor" id="H1068774905"><span class="h3">Aminoglycosides</span><span class="headingEndMark"> — </span>Given that aminoglycosides are nephrotoxic, it is generally believed that aminoglycosides should be used with caution to preserve residual kidney function. (See  <a class="medical medical_review" href="/z/d/html/7214.html" rel="external">"Manifestations of and risk factors for aminoglycoside nephrotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"</a>.)</p><p>However, a number of studies have found no effect of aminoglycoside use on the decline of residual kidney function. As an example, residual kidney function was determined at baseline and at follow-up in 70 patients on peritoneal dialysis who received <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> for peritonitis, 61 individuals with peritonitis who received <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, and 74 control patients without peritonitis [<a href="#rid72">72</a>]. There was no significant difference in the rate of kidney function decline between groups. The lack of effect of aminoglycosides was also observed in a retrospective analysis of 1412 patients [<a href="#rid73">73</a>]. The change in residual kidney function over time was similar in 1075 patients who received empiric aminoglycosides for peritonitis as compared with 339 who did not.</p><p>Another study of 102 patients who received either <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> and netilmicin or cefazolin and <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> showed no differences in residual kidney function between groups [<a href="#rid74">74</a>].</p><p>Thus, limited data suggest that the risk of loss of residual kidney function from short-term use of aminoglycosides for peritonitis is low.</p><p class="headingAnchor" id="H1311823367"><span class="h3">Iodinated radiocontrast agents</span><span class="headingEndMark"> — </span>Iodinated radiocontrast agents can cause acute tubular necrosis, possibly leading to the loss of residual kidney function. (See  <a class="medical medical_review" href="/z/d/html/7241.html" rel="external">"Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management"</a>.)</p><p>However, three studies that prospectively evaluated the effect of contrast on residual kidney function found no loss of function:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, residual kidney function was evaluated at baseline and two weeks after contrast administration in 36 patients on peritoneal dialysis [<a href="#rid75">75</a>]. Thirty-six control patients also underwent determination of residual kidney function two weeks apart. Studies were performed with adequate prehydration and minimal contrast usage (mean urinary volume 104 mL). No differences were found between baseline and follow-up residual kidney function and urine volume in those receiving contrast, and results were not statistically different from controls.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second study of 10 patients on peritoneal dialysis who received nonionic hypo-osmolar contrast media, residual kidney function was measured on days 1 through 7, day 10, and day 30 [<a href="#rid76">76</a>]. There was a mild decline in mean renal clearance on day 6, but clearance subsequently increased back to baseline by day 30.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One study showed no difference in the rate of loss of residual kidney function at six months in 42 patients who were given approximately 100 mL of <a class="drug drug_general" data-topicid="8915" href="/z/d/drug information/8915.html" rel="external">iodixanol</a> contrast compared with 45 patients who did not receive contrast [<a href="#rid77">77</a>].</p><p></p><p>Despite these studies, it may be prudent to avoid high doses of radiocontrast agents in patients on dialysis, if possible. </p><p class="headingAnchor" id="H1191265140"><span class="h2">Decreased sodium intake</span><span class="headingEndMark"> — </span>Decreasing dietary sodium intake may be beneficial for preserving residual kidney function in patients on peritoneal dialysis. In one study that examined the relationship between dietary salt intake (based on a three-day dietary record) and residual kidney function among 62 patients on peritoneal dialysis, high dietary salt intake (≥8 g/day) was associated with an increased rate of decline of residual kidney function compared with nonhigh dietary salt intake [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H548037916"><span class="h2">Other factors</span><span class="headingEndMark"> — </span>Other factors may affect residual kidney function. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac disease [<a href="#rid46">46</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated baseline uric acid levels [<a href="#rid79">79</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Repeated episodes of peritonitis [<a href="#rid80">80,81</a>], although this was not confirmed in all studies [<a href="#rid72">72</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral vascular disease [<a href="#rid81">81</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Larger body mass index (BMI) [<a href="#rid82">82</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes [<a href="#rid82">82</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing age [<a href="#rid83">83</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Higher baseline GFR [<a href="#rid83">83</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension [<a href="#rid83">83</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Proteinuria [<a href="#rid83">83</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Initiation of dialysis after kidney transplant failure [<a href="#rid84">84</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Other nephrotoxic agents (eg, nonsteroidal inflammatory drugs [NSAIDs]) </p><p></p><p class="headingAnchor" id="H1713389190"><span class="h1">MEASUREMENT OF RESIDUAL KIDNEY FUNCTION</span><span class="headingEndMark"> — </span>Residual kidney function can be estimated by determining the urea clearance from a 24-hour urine collection and from the plasma urea. These calculations are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients on hemodialysis (see  <a class="medical medical_review" href="/z/d/html/97967.html" rel="external">"Incorporating residual kidney function into the dosing of intermittent hemodialysis", section on 'Monitoring residual kidney function'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients on peritoneal dialysis (see  <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">"Prescribing peritoneal dialysis", section on 'Addition of residual kidney function'</a>)</p><p></p><p class="headingAnchor" id="H2177309502"><span class="h1">MANAGEMENT OF KIDNEY ALLOGRAFT FAILURE IN PATIENTS STARTING HEMODIALYSIS OR PERITONEAL DIALYSIS</span><span class="headingEndMark"> — </span>The withdrawal of immunosuppression in patients with kidney transplant failure is a complex management issue since prolonged immunosuppression increases the risk of infection and sepsis posttransplant, but overly rapid withdrawal of immunosuppression can lead to symptomatic acute rejection and rapid worsening of kidney function. This issue is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7320.html" rel="external">"Kidney transplantation in adults: Management of the patient with a failed kidney transplant"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical importance of residual kidney function </strong>– Residual kidney function and urinary output are important and beneficial to patients on dialysis. Increased urinary output allows for more flexibility with fluid intake and less fluid removal with dialysis, resulting in the avoidance of hypotension and cramping during hemodialysis. Importantly, among patients on peritoneal dialysis or hemodialysis, continued residual kidney function is associated with improved survival. We therefore suggest the adoption of measures aimed at preserving residual kidney function among patients on peritoneal dialysis (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>) and those on hemodialysis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Survival'</a> above and  <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">"Prescribing peritoneal dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects of dialysis </strong>– Both volume expansion and the high urea load per nephron are rapidly reversed by dialysis of any form. Thus, many patients have a marked reduction in, or even cessation of, urine output when dialysis is instituted. Residual kidney function may be better maintained in patients on peritoneal dialysis compared with hemodialysis. However, comparison studies may not account for modern techniques in hemodialysis that may result in preservation of kidney function. (See <a class="local">'Effects of dialysis on residual kidney function'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors that may affect residual kidney function </strong>– Measures to preserve residual kidney function include avoiding hypotension during and after dialysis, avoiding nephrotoxins as much as possible, and using angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in hypertensive patients.</p><p></p><p class="bulletIndent1">We also maintain or initiate patients on diuretics to increase urine volume although this does not affect residual kidney function. It is preferable to maintain euvolemia with diuretics rather than increased ultrafiltration. (See <a class="local">'Factors that may affect residual kidney function'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022. Available at: https://usrds-adr.niddk.nih.gov/2022.</li><li><a class="nounderline abstract_t">Yeh BP, Tomko DJ, Stacy WK, et al. Factors influencing sodium and water excretion in uremic man. Kidney Int 1975; 7:103.</a></li><li><a class="nounderline abstract_t">Danovitch GM, Bourgoignie J, Bricker NS. Reversibility of the "salt-losing" tendency of chronic renal failure. N Engl J Med 1977; 296:14.</a></li><li><a class="nounderline abstract_t">Feinfeld DA, Danovitch GM. Factors affecting urine volume in chronic renal failure. Am J Kidney Dis 1987; 10:231.</a></li><li><a class="nounderline abstract_t">Bargman JM, Golper TA. The importance of residual renal function for patients on dialysis. Nephrol Dial Transplant 2005; 20:671.</a></li><li><a class="nounderline abstract_t">Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69:1726.</a></li><li><a class="nounderline abstract_t">Bragg-Gresham JL, Fissell RB, Mason NA, et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 2007; 49:426.</a></li><li><a class="nounderline abstract_t">Shafi T, Jaar BG, Plantinga LC, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 2010; 56:348.</a></li><li><a class="nounderline abstract_t">van der Wal WM, Noordzij M, Dekker FW, et al. Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant 2011; 26:2978.</a></li><li><a class="nounderline abstract_t">Obi Y, Rhee CM, Mathew AT, et al. Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. J Am Soc Nephrol 2016; 27:3758.</a></li><li><a class="nounderline abstract_t">You AS, Kalantar-Zadeh K, Obi Y, et al. Residual Urine Output and Mortality in a Prospective Hemodialysis Cohort. Kidney Int Rep 2020; 5:643.</a></li><li><a class="nounderline abstract_t">Naljayan M, Hunt A, McKeon K, et al. Use of incremental peritoneal dialysis: impact on clinical outcomes and quality of life measure. J Nephrol 2023; 36:1897.</a></li><li><a class="nounderline abstract_t">Rottembourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int Suppl 1993; 40:S106.</a></li><li><a class="nounderline abstract_t">Toth-Manikowski SM, Sirich TL, Meyer TW, et al. Contribution of 'clinically negligible' residual kidney function to clearance of uremic solutes. Nephrol Dial Transplant 2020; 35:846.</a></li><li><a class="nounderline abstract_t">Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009; 4:914.</a></li><li><a class="nounderline abstract_t">Krediet RT, Zweers MM, van Westrhenen R, et al. What can we do to preserve the peritoneum? Perit Dial Int 2003; 23 Suppl 2:S14.</a></li><li><a class="nounderline abstract_t">Bargman JM, Thorpe KE, Churchill DN, CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12:2158.</a></li><li><a class="nounderline abstract_t">Lee MJ, Park JT, Park KS, et al. Prognostic Value of Residual Urine Volume, GFR by 24-hour Urine Collection, and eGFR in Patients Receiving Dialysis. Clin J Am Soc Nephrol 2017; 12:426.</a></li><li><a class="nounderline abstract_t">Okazaki M, Obi Y, Shafi T, et al. Residual Kidney Function and Cause-Specific Mortality Among Incident Hemodialysis Patients. Kidney Int Rep 2023; 8:1989.</a></li><li><a class="nounderline abstract_t">Kimura H, Sy J, Okuda Y, et al. A faster decline of residual kidney function and erythropoietin stimulating agent hyporesponsiveness in incident hemodialysis patients. Hemodial Int 2021; 25:60.</a></li><li><a class="nounderline abstract_t">Lee YJ, Rhee CM, Kalantar-Zadeh K. Residual kidney function in twice-weekly hemodialysis: irreplaceable contribution to dialysis adequacy. Ann Transl Med 2018; 6:317.</a></li><li><a class="nounderline abstract_t">Claudino G, Ramos CI, de Andrade LS, et al. The role of residual renal function on potassium intake and excretion in patients on peritoneal dialysis. Int Urol Nephrol 2023; 55:1549.</a></li><li><a class="nounderline abstract_t">Lengton R, van der Willik EM, de Rooij ENM, et al. Effect of residual kidney function and dialysis adequacy on chronic pruritus in dialysis patients. Nephrol Dial Transplant 2023; 38:1508.</a></li><li><a class="nounderline abstract_t">Ogata K. Clinicopathological study of kidneys from patients on chronic dialysis. Kidney Int 1990; 37:1333.</a></li><li><a class="nounderline abstract_t">Rhee CM, Ghahremani-Ghajar M, Obi Y, Kalantar-Zadeh K. Incremental and infrequent hemodialysis: a new paradigm for both dialysis initiation and conservative management. Panminerva Med 2017; 59:188.</a></li><li><a class="nounderline abstract_t">Rhee CM, Unruh M, Chen J, et al. Infrequent dialysis: a new paradigm for hemodialysis initiation. Semin Dial 2013; 26:720.</a></li><li><a class="nounderline abstract_t">Lysaght MJ, Vonesh EF, Gotch F, et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37:598.</a></li><li><a class="nounderline abstract_t">Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11:556.</a></li><li><a class="nounderline abstract_t">Misra M, Vonesh E, Van Stone JC, et al. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 2001; 59:754.</a></li><li><a class="nounderline abstract_t">Jansen MA, Hart AA, Korevaar JC, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62:1046.</a></li><li><a class="nounderline abstract_t">McCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis 1997; 29:576.</a></li><li><a class="nounderline abstract_t">Caramelo C, Alcázar R, Gallar P, et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant 1994; 9:675.</a></li><li><a class="nounderline abstract_t">Lang SM, Bergner A, Töpfer M, Schiffl H. Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors. Perit Dial Int 2001; 21:52.</a></li><li><a class="nounderline abstract_t">Hakim RM, Wingard RL, Husni L, et al. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996; 7:472.</a></li><li><a class="nounderline abstract_t">Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997; 30:366.</a></li><li><a class="nounderline abstract_t">Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17:1814.</a></li><li><a class="nounderline abstract_t">Daugirdas JT, Greene T, Rocco MV, et al. Effect of frequent hemodialysis on residual kidney function. Kidney Int 2013; 83:949.</a></li><li><a class="nounderline abstract_t">Obi Y, Streja E, Rhee CM, et al. Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study. Am J Kidney Dis 2016; 68:256.</a></li><li><a class="nounderline abstract_t">Vilar E, Kaja Kamal RM, Fotheringham J, et al. A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function. Kidney Int 2022; 101:615.</a></li><li class="breakAll">Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets) (INCHVETS). Available at: https://clinicaltrials.gov/ct2/show/NCT05465044.</li><li><a class="nounderline abstract_t">Lee Y, Okuda Y, Sy J, et al. Ultrafiltration Rate Effects Declines in Residual Kidney Function in Hemodialysis Patients. Am J Nephrol 2019; 50:481.</a></li><li><a class="nounderline abstract_t">Lee YJ, Okuda Y, Sy J, et al. Ultrafiltration Rate, Residual Kidney Function, and Survival Among Patients Treated With Reduced-Frequency Hemodialysis. Am J Kidney Dis 2020; 75:342.</a></li><li><a class="nounderline abstract_t">Hiroshige K, Yuu K, Soejima M, et al. Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int 1996; 16:307.</a></li><li><a class="nounderline abstract_t">Hufnagel G, Michel C, Queffeulou G, et al. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 1999; 14:1224.</a></li><li><a class="nounderline abstract_t">Michels WM, Verduijn M, Grootendorst DC, et al. Decline in residual renal function in automated compared with continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6:537.</a></li><li><a class="nounderline abstract_t">Holley JL, Aslam N, Bernardini J, et al. The influence of demographic factors and modality on loss of residual renal function in incident peritoneal dialysis patients. Perit Dial Int 2001; 21:302.</a></li><li><a class="nounderline abstract_t">Rabindranath KS, Adams J, Ali TZ, et al. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease. Cochrane Database Syst Rev 2007; :CD006515.</a></li><li><a class="nounderline abstract_t">Cnossen TT, Usvyat L, Kotanko P, et al. Comparison of outcomes on continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis: results from a USA database. Perit Dial Int 2011; 31:679.</a></li><li><a class="nounderline abstract_t">Kim S, Oh J, Kim S, et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24:2899.</a></li><li><a class="nounderline abstract_t">Kim S, Oh KH, Oh J, et al. Biocompatible peritoneal dialysis solution preserves residual renal function. Am J Nephrol 2012; 36:305.</a></li><li><a class="nounderline abstract_t">Ha IS, Yap HK, Munarriz RL, et al. Risk factors for loss of residual renal function in children treated with chronic peritoneal dialysis. Kidney Int 2015; 88:605.</a></li><li><a class="nounderline abstract_t">Fan SL, Pile T, Punzalan S, et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73:200.</a></li><li><a class="nounderline abstract_t">Szeto CC, Chow KM, Lam CW, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22:552.</a></li><li><a class="nounderline abstract_t">Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23:1097.</a></li><li><a class="nounderline abstract_t">Wang J, Zhu N, Yuan W. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis. Nephron 2015; 129:155.</a></li><li><a class="nounderline abstract_t">Chang TI, Ryu DR, Yoo TH, et al. Effect of Icodextrin Solution on the Preservation of Residual Renal Function in Peritoneal Dialysis Patients: A Randomized Controlled Study. Medicine (Baltimore) 2016; 95:e2991.</a></li><li><a class="nounderline abstract_t">Kim JK, Kim YS, Song YR, et al. Excessive Weight Gain during the First Year of Peritoneal Dialysis Is Associated with Inflammation, Diabetes Mellitus, and a Rapid Decrease in Residual Renal Function. PLoS One 2015; 10:e0139033.</a></li><li><a class="nounderline abstract_t">Htay H, Cho Y, Pascoe EM, et al. Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The balANZ Trial. Perit Dial Int 2017; 37:283.</a></li><li><a class="nounderline abstract_t">Chang TI, Kang EW, Kim HW, et al. Low Serum Bicarbonate Predicts Residual Renal Function Loss in Peritoneal Dialysis Patients. Medicine (Baltimore) 2015; 94:e1276.</a></li><li><a class="nounderline abstract_t">Szeto CC, Kwan BC, Chow KM, et al. Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 2015; 35:180.</a></li><li><a class="nounderline abstract_t">Lameire N, Van Biesen W. The impact of residual renal function on the adequacy of peritoneal dialysis. Perit Dial Int 1997; 17 Suppl 2:S102.</a></li><li><a class="nounderline abstract_t">McKane W, Chandna SM, Tattersall JE, et al. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 2002; 61:256.</a></li><li><a class="nounderline abstract_t">Gunal AI, Kirciman E, Guler M, et al. Should the preservation of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients? Ren Fail 2004; 26:405.</a></li><li><a class="nounderline abstract_t">Marants R, Grant C, Lee T, McIntyre CW. Renal perfusion falls during hemodialysis: An explanation for the loss of residual renal function in dialysis patients [Abstract]. J Am Soc Nephrol 2016; 27:327A.</a></li><li><a class="nounderline abstract_t">Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001; 59:1128.</a></li><li><a class="nounderline abstract_t">van Olden RW, van Meyel JJ, Gerlag PG. Acute and long-term effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am J Nephrol 1992; 12:351.</a></li><li><a class="nounderline abstract_t">Zhang L, Zeng X, Fu P, Wu HM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients. Cochrane Database Syst Rev 2014; :CD009120.</a></li><li><a class="nounderline abstract_t">Kjaergaard KD, Peters CD, Jespersen B, et al. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis 2014; 64:892.</a></li><li><a class="nounderline abstract_t">Xydakis D, Papadogiannakis A, Sfakianaki M, et al. Residual renal function in hemodialysis patients: the role of Angiotensin-converting enzyme inhibitor in its preservation. ISRN Nephrol 2013; 2013:184527.</a></li><li><a class="nounderline abstract_t">K/DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy. Am J Kidney Dis 2006; 47(Supp 4):S1.</a></li><li><a class="nounderline abstract_t">Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006; 48 Suppl 1:S2.</a></li><li><a class="nounderline abstract_t">Baker RJ, Senior H, Clemenger M, Brown EA. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41:670.</a></li><li><a class="nounderline abstract_t">Badve SV, Hawley CM, McDonald SP, et al. Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. Nephrol Dial Transplant 2012; 27:381.</a></li><li><a class="nounderline abstract_t">Lui SL, Cheng SW, Ng F, et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function. Kidney Int 2005; 68:2375.</a></li><li><a class="nounderline abstract_t">Moranne O, Willoteaux S, Pagniez D, et al. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol Dial Transplant 2006; 21:1040.</a></li><li><a class="nounderline abstract_t">Dittrich E, Puttinger H, Schillinger M, et al. Effect of radio contrast media on residual renal function in peritoneal dialysis patients--a prospective study. Nephrol Dial Transplant 2006; 21:1334.</a></li><li><a class="nounderline abstract_t">Janousek R, Krajina A, Peregrin JH, et al. Effect of intravascular iodinated contrast media on natural course of end-stage renal disease progression in hemodialysis patients: a prospective study. Cardiovasc Intervent Radiol 2010; 33:61.</a></li><li><a class="nounderline abstract_t">Gong N, Zhou C, Hu J, et al. High-Salt Diet Accelerated the Decline of Residual Renal Function in Patients With Peritoneal Dialysis. Front Med (Lausanne) 2021; 8:728009.</a></li><li><a class="nounderline abstract_t">Park JT, Kim DK, Chang TI, et al. Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients. Nephrol Dial Transplant 2009; 24:3520.</a></li><li><a class="nounderline abstract_t">Shin SK, Noh H, Kang SW, et al. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19:138.</a></li><li><a class="nounderline abstract_t">Tian SL, Tian XK, Han QF, et al. Presence of peripheral arterial disease predicts loss of residual renal function in incident CAPD patients. Perit Dial Int 2012; 32:67.</a></li><li><a class="nounderline abstract_t">Singhal MK, Bhaskaran S, Vidgen E, et al. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 2000; 20:429.</a></li><li><a class="nounderline abstract_t">Perl J, Bargman JM. The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis 2009; 53:1068.</a></li><li><a class="nounderline abstract_t">Madar H, Korzets A, Ori Y, et al. Residual renal function in peritoneal dialysis after renal transplant failure. Perit Dial Int 2010; 30:470.</a></li></ol></div><div id="topicVersionRevision">Topic 1941 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://usrds-adr.niddk.nih.gov/2022" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022. Available at: https://usrds-adr.niddk.nih.gov/2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1113451" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Factors influencing sodium and water excretion in uremic man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/618364" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Reversibility of the "salt-losing" tendency of chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3631070" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Factors affecting urine volume in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755759" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The importance of residual renal function for patients on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16612329" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The importance of residual renal function in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336704" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20605303" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21317411" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169576" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32405586" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Residual Urine Output and Mortality in a Prospective Hemodialysis Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37644364" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Use of incremental peritoneal dialysis: impact on clinical outcomes and quality of life measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8445831" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Residual renal function and recovery of renal function in patients treated by CAPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879076" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Contribution of 'clinically negligible' residual kidney function to clearance of uremic solutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357245" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hemodialysis-induced cardiac injury: determinants and associated outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986535" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : What can we do to preserve the peritoneum?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11562415" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28228465" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prognostic Value of Residual Urine Volume, GFR by 24-hour Urine Collection, and eGFR in Patients Receiving Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37849997" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Residual Kidney Function and Cause-Specific Mortality Among Incident Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33034069" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A faster decline of residual kidney function and erythropoietin stimulating agent hyporesponsiveness in incident hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30363974" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Residual kidney function in twice-weekly hemodialysis: irreplaceable contribution to dialysis adequacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36648740" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The role of residual renal function on potassium intake and excretion in patients on peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36549655" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of residual kidney function and dialysis adequacy on chronic pruritus in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2345429" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinicopathological study of kidneys from patients on chronic dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28090764" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incremental and infrequent hemodialysis: a new paradigm for both dialysis initiation and conservative management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24016197" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Infrequent dialysis: a new paradigm for hemodialysis initiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1768496" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The influence of dialysis treatment modality on the decline of remaining renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703680" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Predictors of loss of residual renal function among new dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168959" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12164889" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Predictors of the rate of decline of residual renal function in incident dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9100048" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7970095" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11280496" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8704114" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292565" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12270990" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23344474" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of frequent hemodialysis on residual kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26867814" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34418414" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34418414" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31661683" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ultrafiltration Rate Effects Declines in Residual Kidney Function in Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31813665" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ultrafiltration Rate, Residual Kidney Function, and Survival Among Patients Treated With Reduced-Frequency Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8761546" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Rapid decline of residual renal function in patients on automated peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344365" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The influence of automated peritoneal dialysis on the decrease in residual renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393494" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Decline in residual renal function in automated compared with continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11475347" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The influence of demographic factors and modality on loss of residual renal function in incident peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443624" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20829519" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of outcomes on continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis: results from a USA database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258384" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23007025" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Biocompatible peritoneal dialysis solution preserves residual renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25874598" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risk factors for loss of residual renal function in children treated with chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17914351" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005526" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22440906" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25765060" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043667" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of Icodextrin Solution on the Preservation of Residual Renal Function in Peritoneal Dialysis Patients: A Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26406589" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Excessive Weight Gain during the First Year of Peritoneal Dialysis Is Associated with Inflammation, Diabetes Mellitus, and a Rapid Decrease in Residual Renal Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27935537" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The balANZ Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26252296" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Low Serum Bicarbonate Predicts Residual Renal Function Loss in Peritoneal Dialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497594" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9163808" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The impact of residual renal function on the adequacy of peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786108" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15462109" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Should the preservation of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Renal perfusion falls during hemodialysis: An explanation for the loss of residual renal function in dialysis patients [Abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231370" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1489005" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Acute and long-term effects of therapy with high-dose furosemide in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24953826" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25011693" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24959534" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Residual renal function in hemodialysis patients: the role of Angiotensin-converting enzyme inhibitor in its preservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : K/DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16813990" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical practice guidelines for hemodialysis adequacy, update 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612992" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Empirical aminoglycosides for peritonitis do not affect residual renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21633101" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221243" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16352623" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of iodinated contrast agents on residual renal function in PD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16046499" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of radio contrast media on residual renal function in peritoneal dialysis patients--a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19830486" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effect of intravascular iodinated contrast media on natural course of end-stage renal disease progression in hemodialysis patients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34595194" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : High-Salt Diet Accelerated the Decline of Residual Renal Function in Patients With Peritoneal Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19491381" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10357184" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21532004" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Presence of peripheral arterial disease predicts loss of residual renal function in incident CAPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007375" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19394737" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The importance of residual kidney function for patients on dialysis: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628109" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Residual renal function in peritoneal dialysis after renal transplant failure.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
